Research Paper Volume 13, Issue 13 pp 17370—17379

Baicalein ameliorates osteoporosis via AKT/FOXO1 signaling

BN regulates osteogenesis via AKT/FOXO1 signaling. (A) QRT-PCR analysis shows FOXO1 levels in GIO model MC3T3-E1 cells treated with BN (1μM, 10 μM, and 100 μM). (B) QRT-PCR analysis shows AKT mRNA levels in control-siRNA- and AKT siRNA-transfected MC3T3-E1 cells. (C) QRT-PCR analysis shows the levels of FOXO1 in control-siRNA- and AKT siRNA-transfected GIO model MC3T3-E1 cells treated with BN (1μM, 10 μM, and 100 μM). (D–G) QRT-PCR analysis shows the levels of bone turnover markers (ALP, OCN, Runx2, and Col 1) in control-siRNA- and AKT siRNA-transfected GIO model MC3T3-E1 cells treated with BN (1μM, 10 μM, and 100 μM). (H, I) ALP staining results of control-siRNA- and AKT siRNA-transfected GIO model MC3T3-E1 cells treated with BN (1μM, 10 μM, and 100 μM). The data are shown as means±SD of 3 independent experiments.

Figure 7. BN regulates osteogenesis via AKT/FOXO1 signaling. (A) QRT-PCR analysis shows FOXO1 levels in GIO model MC3T3-E1 cells treated with BN (1μM, 10 μM, and 100 μM). (B) QRT-PCR analysis shows AKT mRNA levels in control-siRNA- and AKT siRNA-transfected MC3T3-E1 cells. (C) QRT-PCR analysis shows the levels of FOXO1 in control-siRNA- and AKT siRNA-transfected GIO model MC3T3-E1 cells treated with BN (1μM, 10 μM, and 100 μM). (DG) QRT-PCR analysis shows the levels of bone turnover markers (ALP, OCN, Runx2, and Col 1) in control-siRNA- and AKT siRNA-transfected GIO model MC3T3-E1 cells treated with BN (1μM, 10 μM, and 100 μM). (H, I) ALP staining results of control-siRNA- and AKT siRNA-transfected GIO model MC3T3-E1 cells treated with BN (1μM, 10 μM, and 100 μM). The data are shown as means±SD of 3 independent experiments.